You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Production of NIST/UCSF Breast Phantom for Magnetic Resonance Imagaing (MRI)

    SBC: Phantom Laboratory            Topic: N/A

    his project involves the commercialization of the breast phantom designed by NIST and University of California, San Francisco (UCSF) for quantitative magnetic resonance imaging (MRI). The breast phantom consists of two independent phantoms, one focused on diffusion MRI measurements and the other focused on accurate measurements of fat and fibroglandular tissue properties. The proposed phantom is o ...

    SBIR Phase I 2014 Department of CommerceNational Institute of Standards and Technology
  2. Dynamic Frequency Passive Millemeter-Wave Radiometer Based on Optical Up-Conversion

    SBC: Phase Sensitive Innovations, Inc.            Topic: 94

    Passive microwave sensors aboard satellites provide valuable information regarding weather conditions by measuring atmospheric attenuation over a broad range of frequencies from 0-200 GHz. Additional ground-based sensors are desirable to provide complementary upward looking measurements that can be used to refine existing attenuation models. Operating over such a large bandwidth, however, places ...

    SBIR Phase II 2014 Department of CommerceNational Oceanic and Atmospheric Administration
  3. A Novel Small Molecule Therapeutic for Alcoholic Chronic Pancreatitis

    SBC: Angion Biomedica Corp.            Topic: NIAAA

    DESCRIPTION (provided by applicant): Chronic Pancreatitis (CP) is characterized by continuous or recurrent inflammation of the pancreas that leads to permanent destruction of the pancreas resulting in exocrine and endocrine insufficiency. CP is a common disorder associated with significant morbidity and mortality with an incidence of 8.2 and a prevalence of 27.4 per 100 000 population. The etiolog ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. PRECLINICAL TESTING OF HUMAN GHRELIN AND GROWTH HORMONE FOR SEPSIS IN THE ELDLY

    SBC: THERASOURCE, LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The ultimate goal of our proposal is to develop a novel therapeutic approach that will save lives of aged septic patients. Sepsis is the most common cause of death in the non-cardiac intensive care units (ICU). It is particularly a serious problem in the geriatric population. The elderly (e 65 years of age) accounts for 12% of the US population but 65% of sepsi ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Development, Production and Testing of VLP based Respiratory Syncytial Virus (RSV

    SBC: TechnoVax, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop a safe and efficacious virus-like particle (VLP) based-respiratory syncytial virus (RSV) vaccine to prevent the disease caused by this pathogen. The respiratory illnesses provokedby RSV in infants, children and the elderly are of global economical and public health impact. A recent worldwide estimate [5] indicates that ov ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. A Therapeutic for Radiation Induced Lung Injury

    SBC: Angion Biomedica Corp.            Topic: NIAID

    DESCRIPTION (provided by applicant): Nuclear accidents and terrorism present a serious threat for causing mass-casualty scenarios. In radiation events, many people receive non-uniform whole-body or partial-body irradiation. The risk of exposure to ionizingradiation due to terrorist activities could result in acute injury as well as long-term adverse health effects in thousands of people. The lung ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil

    SBC: ADJUVANCE TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Antitumor and anti-infectious disease vaccines require adjuvants in order to obtain optimal immunogenicity and therapeutic and protective efficacy. QS-21 is a natural saponin fraction that significantly out-performs other adjuvants in eliciting productive antibody and T-cell responses. It has remained the adjuvant of choice and has proven it's potency as i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Endotoxin Neutralization as a Biomonitor for HIV Disease Progression

    SBC: BIODTECH, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Endotoxin neutralization in human plasma is an excellent indicator of chronic immune activation, which is the most accurate predictor of mortality in HIV. Recently we developed an assay using endotoxin neutralization asan indicator of bacterial translocation. This assay is accurate in discriminating control patients from those with inflammatory bowel disease in ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Discovery of inhibitors of the metabolic oncogene 3-phosphoglycerate dehydrogenas

    SBC: Kadmon Corporation, LLC            Topic: NCI

    DESCRIPTION (provided by applicant): Many profound metabolic alterations have been described in solid tumors which present attractive therapeutic targets. One recently described metabolic oncogene is 3- phosphoglycerate dehydrogenase (PHGDH), the rate-limiting step in the pathway synthesizing serine and glycine for proteins, lipids, folate and nucleotide metabolism. The PHGDH gene is amplified a ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Deimmunized TLR5 Agonist for Anticancer Therapy

    SBC: BUFFALO BIOLABS, LLC            Topic: NCI

    ABSTRACT: Radiotherapy is widely used to treat various types of cancer; however, its effectiveness is frequently limited by severe adverse effects resulting from radiation-induced damage to normal tissues in the tumor environment. Due to the scale of thisproblem and the current lack of safe and effective countermeasures against radiation toxicity, development of such agents is of broad significanc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government